Medicare Part D coverage · valsartan · RxCUI 1996254
valsartan 4 MG/ML Oral Solution
Per the CMS 2026 Part D formulary file, valsartan 4 MG/ML Oral Solution is covered by 10 Medicare Part D plans (0.2% of enrollable products), averaging Tier 2.8, with prior authorization required on 0% of covering formularies.
- 0.2%
- Plan coverage
- 10
- Plans covering
- T2.8
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for valsartan 4 MG/ML Oral Solution
Per the CMS 2026 Part D formulary file, valsartan 4 MG/ML Oral Solution (RxNorm concept RXCUI 1996254, generic name valsartan) appears on 5 distinct formulary files spanning 10 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 2.8.
Real-world access to valsartan 4 MG/ML Oral Solution depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,011,848 Part D beneficiaries filled valsartan 4 MG/ML Oral Solution in 2023, with total plan-and-beneficiary spending of $147,076,944 and an average per-beneficiary annual cost of $145.35. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry valsartan 4 MG/ML Oral Solution today.
Coverage Details
- Formularies covering
- 5
- Plans covering
- 10
- Coverage rate
- 0.2%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,011,848
- Total spending
- $147,076,944
- Avg per beneficiary
- $145.35
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering valsartan 4 MG/ML Oral Solution
10 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Mass General Brigham SCO (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | No | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | No | $0 | MA |
| Aspire Health Protect (HMO) | Aspire Health Plan | T2 | No | $0 | CA |
| Aspire Health Value (HMO) | Aspire Health Plan | T2 | No | $22.60 | CA |
| Aspire Health Advantage (HMO) | Aspire Health Plan | T2 | No | $44.80 | CA |
| Aspire Health Plus (HMO-POS) | Aspire Health Plan | T2 | No | $119.20 | CA |
| Mass General Brigham Advantage (PPO) | Mass General Brigham Health Plan, Inc. | T5 | No | $0 | MA |
| Mass General Brigham Advantage Secure (HMO-POS) | Mass General Brigham Health Plan, Inc. | T5 | No | $62.00 | MA |
| Mass General Brigham Advantage Premier (PPO) | Mass General Brigham Health Plan, Inc. | T5 | No | $79.70 | MA |
| Mass General Brigham Advantage Signature (PPO) | Mass General Brigham Health Plan, Inc. | T5 | No | $147.20 | MA |
Frequently Asked Questions
Is valsartan 4 MG/ML Oral Solution covered by Medicare Part D?
Yes, valsartan 4 MG/ML Oral Solution is covered by 10 Medicare Part D plans (0.2% of all Part D formularies).
What tier is valsartan 4 MG/ML Oral Solution on Medicare Part D plans?
valsartan 4 MG/ML Oral Solution averages Tier 2.8 across Part D plans, ranging from Tier 1 to Tier 5.
Does valsartan 4 MG/ML Oral Solution require prior authorization?
0% of Part D formularies require prior authorization for valsartan 4 MG/ML Oral Solution. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on valsartan 4 MG/ML Oral Solution?
In 2023, total Medicare Part D spending on valsartan 4 MG/ML Oral Solution was $147,076,944, covering 1,011,848 beneficiaries. The average spend per beneficiary was $145.35.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- bromocriptine 2.5 MG Oral Tablet T2.8
- cyclosporine 25 MG Oral Capsule T2.8
- emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet T2.8
- ampicillin 1000 MG Injection T2.8
- estradiol 0.01 MG Vaginal Insert T2.8
- acetaminophen 21.7 MG/ML / hydrocodone bitartrate 0.5 MG/ML Oral Solution T2.8
Similar prior-authorization rate
- metronidazole 10 MG/ML Topical Cream [Noritate] 0% PA
- 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] 0% PA
- buspirone hydrochloride 10 MG Oral Capsule [Bucapsol] 0% PA
- diflunisal 375 MG Oral Tablet [Dolobid] 0% PA
- hydrocortisone 1 MG/ML Oral Solution [Khindivi] 0% PA
- indomethacin 50 MG Rectal Suppository [Indocin] 0% PA